Wedbush Upgrades NovoCure to Neutral, Lowers Price Target to $46
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten upgrades NovoCure (NASDAQ:NVCR) from Underperform to Neutral and lowers the price target from $53 to $46.
June 07, 2023 | 8:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
NovoCure upgraded to Neutral by Wedbush, with a lowered price target of $46.
The news directly mentions NovoCure (NVCR) and its upgrade from Underperform to Neutral by Wedbush analyst David Nierengarten. The price target has been lowered from $53 to $46, which may have a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100